A diversified and integrated pipeline of products in Neurology
Our pipeline is focused on metabolic dysfunction in neurological diseases with high unmet needs, across therapeutic and diagnostic spectrums. Our pipeline leverages the knowledge and experience of Cerecin’s leadership in research and understanding of ketosis and its role in neurometabolism and bioenergetics for the management of AD, Migraine and pediatric epilepsy. We have two assets in the preclinical phase: CER-022 is being investigated for use in diagnosing specific conditions based on ketone metabolism and CER-081, a ketone precursor, is being investigated for use in acute neurological conditions.
Entering global Phase 3 pivotal trial to study CER0001 in treatment of mild to moderate Alzheimer’s disease in APOE4 negative patientsLearn More
Completed Phase 2a study in migraine prevention. Currently planning Phase 3 global trialLearn More
Encouraging data from Pilot Phase 2a study in 2023 and preparation underway to initiate global Phase 3 pivotal trialLearn More
Radiolabeled tracer in preclinical stage being studied for the diagnosis of neurological & other conditions having underlying dysfunction in ketone metabolism
Ketone precursor in preclinical stage with a parenteral mode of administration with applications being evaluated in treatment of acute neurological conditions such as Traumatic Brain Injury, Stroke among others
Our Therapeutic Areas
Alzheimer’s disease (AD) is an age-associated, neurodegenerative disease characterized by a progressive decline in memory and language, and, pathologically, by accumulation of senile plaques and neurofibrillary tangles in the brain.
Infantile Spasms (IS), also known as West Syndrome, is a form of epilepsy that occurs in infants, characterized by spasms that are rapid, muscular contractions lasting one to two seconds, in clusters ranging from a few spasms to more than 100 spasms per cluster, along with hypsarrhythmia. It is a complex, rare and devastating disorder which can lead to severe consequences if not treated early. The majority of infants with IS present before the age of 1 year.
Migraine is the third most common disease in the world, affecting 1 billion people worldwide, concentrated in populations which are of productive age. Migraine is characterized by attacks of moderate to severe throbbing head pain. There is currently no cure for this neurologic disorder.